Single IRB Policy For Multi-Site Trials May Soon Get White House OK; NCI Hopeful
Executive Summary
The White House appears close to finalizing a policy that would allow multi-site clinical trials to use only one institutional review board, which National Cancer Institute and other officials think could speed up and improve the process.
You may also be interested in...
Central IRBs, Data Security Standards Feature In Overhaul Of "Common Rule"
Clinical trials that take place at multiple U.S. sites and are covered by the "Common Rule" of federal regulations relating to human subject protection could soon be required to use a single institutional review board of record, under a proposed revision.
Central IRBs, Data Security Standards Feature In Overhaul Of "Common Rule"
Clinical trials that take place at multiple U.S. sites and are covered by the "Common Rule" of federal regulations relating to human subject protection could soon be required to use a single institutional review board of record, under a proposed revision.
Can Pfizer’s "Virtual Trial" Change The Game, Cut Development Costs?
As drug makers seek ways to reduce the cost of clinical trials, Pfizer thinks the solution could be asking patients to reach into their own pockets – for their cell phones.